FDA Approves First Drug to Prevent aGVHD

December 16, 2021

The Food and Drug Administration approved abatacept (Orencia, Bristol Myers Squibb) yesterday to prevent acute graft versus host disease (aGVHD) in combination with certain immunosuppressants. Abatacept may be used in adults and pediatric patients two years of age or older who are undergoing hematopoietic stem cell transplantation from an unrelated donor. This is the first FDA drug approval for aGVHD prevention.